#USA #Boston #Field Medical #AF Symposium #PFA Technology

Field Medical Presents Innovative Clinical Trial Results at AF Symposium 2026

Field Medical, Inc., a clinical-stage medical technology company, has made headlines by presenting groundbreaking clinical trial data for their Pulse Field Ablation (PFA) solutions aimed at treating complex cardiac arrhythmias. This remarkable development was unveiled at the 31st Annual International Symposium on Atrial Fibrillation (AF) held in Boston from February 5 to 7, 2026.

New Waveforms and Clinical Insights

During the symposium, Field Medical introduced findings from their first human study, aptly named the Field PULSE trial. This trial evaluated a novel high-voltage waveform delivered in less than a second through the FieldForce™ Ablation System, a contact-detectable focal catheter. This approach enables instantaneous ablation, allowing for precise, point-by-point energy delivery without requiring prolonged contact with the tissue, a significant advancement in arrhythmia treatment.

Dr. Vivek Y. Reddy, the principal investigator of the Field PULSE trial and an electrophysiologist at Mount Sinai in New York, emphasized the innovative potential of this new technology. "By eliminating the need for sustained contact between the tissue and the catheter, the delivery of a pulse field lasting less than a second allows for effective point-by-point ablation and tailored lesion sets."

Study Highlights

The Field PULSE trial showcased several key findings that underline the efficacy of the new ablation method:

• - Instantaneous Energy Delivery: Lesions were created in under 200 milliseconds, facilitating rapid point-by-point ablation.
• - Procedure Efficiency: The median time for achieving bilateral pulmonary vein isolation was an impressive 12.5 minutes, with the fastest recorded at just 7.7 minutes.
• - Durability of Results: The remapping process highlighted a progressive improvement in pulmonary vein isolation durability, with rates of 94.2% by vein and 84.6% by patient.

Safety Outcomes

Impressively, the study reported no serious adverse events related to the device. Additionally, there were no cases of acute kidney injury, phrenic nerve paralysis, or clinically relevant hemolysis. Among 14 patients assessed through brain MRI, no silent brain lesions (DWI+/FLAIR+) were found.

These encouraging results expand the clinical evidence for Field Medical's high-voltage focal PFA approach beyond ventricular arrhythmias, paving the way for effective treatment of atrial fibrillation (AF).

Future Directions

With established data showing the efficacy of their methods, Field Medical aims to further develop a versatile ablation platform capable of addressing arrhythmias across all heart chambers. Steven Mickelsen, M.D., founder and Chief Technology Officer of Field Medical added, "The results from Field PULSE solidify our approach to designing a focal PFA aimed specifically at overcoming the fundamental challenges posed by existing methods. By executing each ablation point in a fraction of a second, we lessen the dependence on prolonged catheter stability and mitigate the impacts of cardiac movement."

The data was presented during the late-breaking clinical trials session at the AF Symposium 2026, with additional presentations planned. Future discussions will focus on maximizing lesion depth using high-voltage PFA waveforms and their application in AF treatment using the FieldForce system.

About FieldForce™ Ablation System

The FieldForce Ablation System is a proprietary focal PFA device designed to deliver targeted, high-intensity electric fields using the innovative FieldBending™ technology. It aims to facilitate both atrial and ventricular ablation while focusing on improving procedural efficiency.

Field Medical, founded in 2022, is committed to advancing PFA solutions for complex cardiac arrhythmias. Their dedication to innovation has already earned them a pioneering device designation and inclusion in the FDA's TAP pilot program for ventricular tachycardia indications. For more details, visit www.fieldmedicalinc.com or follow them on LinkedIn, X, and YouTube.

The FieldForce™ system is an experimental device whose use is limited by federal law to investigational purposes only.